What it is
Mazdutide is a dual agonist of the GLP-1 and glucagon receptors.
Unpacking that: GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases when you eat, which suppresses appetite. Glucagon is a different hormone, made by the pancreas, which raises blood sugar and increases the rate at which the body burns energy. An agonist is something that copies a hormone and switches on the same receptors. "Dual" means Mazdutide acts on both.
It was originally designed to treat Type-2 diabetes and obesity.
What it does: it increases insulin secretion, lowers blood sugar, increases energy expenditure, improves fat metabolism in the liver, delays stomach emptying, and causes weight loss.
Clinical trials showed an average 9.5% weight loss within 12 weeks, and 14% average weight loss at 48 weeks.
Mazdutide is regarded as the safest GLP-1 peptide, and side effects are generally minimal.
It arrives as a dry powder in a sealed vial. You add bacteriostatic water — sterile water with a preservative, so it keeps for weeks — then inject just under the skin, a subcutaneous injection, once a week.
Mazdutide is a dual GLP-1 / glucagon receptor agonist designed for Type-2 diabetes and obesity.
Mechanistic profile: increased insulin secretion, lowered blood glucose, increased energy expenditure, improved hepatic fat metabolism, delayed gastric emptying, and weight loss. The glucagon receptor arm is what supplies the energy-expenditure and hepatic-lipid components — distinct from the GLP-1 / GIP dual agonists, which add a second incretin instead.
Trial outcomes cited: 9.5% average weight loss at 12 weeks; 14% at 48 weeks.
Mazdutide is regarded as the safest GLP-1 peptide with generally minimal side effects, and its reported adverse event list is correspondingly short. The contraindication list is a single item: pregnancy or nursing.
Administration: subcutaneous, once weekly, reconstituted in bacteriostatic water, with a four-dose ladder from 2 mg to 6 mg.
What it does
Weight: clinical trials showed an average 9.5% weight loss within 12 weeks and 14% at 48 weeks. It burns calories more efficiently and boosts metabolic functions generally.
Blood sugar: it increases insulin secretion and lowers blood sugar levels, and regulates blood sugar.
Fat and liver: it improves fat metabolism in the liver, reduces liver fat content, and reduces liver inflammation. It also improves lipid levels — the fats in your blood, such as cholesterol.
Stomach: it delays stomach emptying, which prolongs the feeling of fullness after eating.
Heart: it improves cardiovascular health and blood pressure.
Bone: it increases bone health, promotes bone formation while inhibiting bone breakdown, and reduces the risk of fractures and osteoporosis — the thinning of bone that makes it fragile.
Glycaemic: increased insulin secretion, lowered blood glucose, improved glucose regulation.
Energetic: increased energy expenditure and more efficient caloric burn — the glucagon arm's contribution.
Hepatic: improved hepatic fat metabolism, reduced liver fat content, reduced liver inflammation.
Gastric: delayed gastric emptying.
Body composition: 9.5% average weight loss at 12 weeks; 14% at 48 weeks.
Lipids and cardiovascular: improved lipid profile, improved cardiovascular health, improved blood pressure.
Skeletal: increased bone health with promotion of bone formation and inhibition of resorption; reduced fracture and osteoporosis risk — a formation-favouring remodelling shift rather than a neutral skeletal profile.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Average 9.5% weight loss within 12 weeks and 14% at 48 weeks in clinical trials.Human trials
- Boosts metabolic functions.Limited human data
- Weight loss.Human trials
- Burns calories more efficiently.Animal or lab only
- Regulates blood sugar.Human trials
- Improves lipid levels — the fats in your blood, such as cholesterol.Human trials
- Better cardiovascular health.Limited human data
- Improves blood pressure.Human trials
- Increases bone health.Animal or lab only
- Promotes bone formation and inhibits bone breakdown.Animal or lab only
- Reduces the risk of bone fracture and osteoporosis, the thinning of bone that makes it fragile.Anecdotal
- Reduces liver fat content.Human trials
- Reduces liver inflammation.Limited human data
- Regarded as the safest GLP-1 peptide, with generally minimal side effects.Anecdotal
- 9.5% average weight loss at 12 weeks; 14% at 48 weeks.Human trials
- Boosted metabolic function and more efficient caloric burn.Animal or lab only
- Weight loss.Human trials
- Glycaemic regulation.Human trials
- Improved lipid profile.Human trials
- Improved cardiovascular health.Limited human data
- Improved blood pressure.Human trials
- Increased bone health.Animal or lab only
- Promotes bone formation, inhibits resorption.Animal or lab only
- Reduced fracture and osteoporosis risk.Anecdotal
- Reduced hepatic fat content.Human trials
- Reduced hepatic inflammation.Limited human data
- Regarded as the safest agent in the GLP-1 class.Anecdotal
Reconstitution and dosing
One vial size is covered: 10 mg, mixed with 1 mL (100 units) of bacteriostatic water. "Units" means the marks on an insulin syringe — 100 units is 1 mL.
Inject under the skin, once a week, on the same day each week.
Stay at each dose level for a minimum of four weeks before increasing. Start low, and only increase when the current dose is well tolerated.
The ladder has four steps: 2 mg, 3 mg, 4.5 mg, and 6 mg.
No cycle length or washout period has been established for Mazdutide.
Single presentation: 10 mg in 1 mL (100 units) of bacteriostatic water, giving 10 mg/mL.
Subcutaneous, once weekly, fixed day. Minimum four weeks at each dose level before escalation; start low and escalate only on tolerance.
Four-step ladder: 2 mg, 3 mg, 4.5 mg, 6 mg. Steps are non-uniform — 1 mg, then 1.5 mg, then 1.5 mg.
No cycle length or washout has been specified.
10 mg vial
Mix with 1 mL (100 units) of bacteriostatic water.
10 mg/mL · 100 mcg per unit
Frequency: Once per week, same day each week, subcutaneous; minimum 4 weeks at each dose level before increasing; start low and only increase when well tolerated
| When | Dose | Draw | How often |
|---|---|---|---|
| 2 mg | 2 mg | 20 units | once weekly |
| 3 mg | 3 mg | 30 units | once weekly |
| 4.5 mg | 4.5 mg | 45 units | once weekly |
| 6 mg | 6 mg | 60 units | once weekly |
10 mg in 1 mL is 10 mg/mL, or 100 mcg per unit. Draw 20 units (0.2 mL) for 2000 mcg.
Who should avoid it
- Anyone pregnant or nursing. This is the only documented contraindication for Mazdutide.
- Talk to a doctor before starting.
- Pregnancy or nursing — the sole documented contraindication.
- No other exclusions, cautions, or drug interactions have been documented for Mazdutide. Treat that brevity as a limit of the available documentation rather than as an established clean profile; the sibling GLP pages carry far longer lists.
Side effects
- Side effects are generally minimal.
- Injection site reaction — redness, swelling, and/or itching.
- Abdominal distension — a bloated, swollen belly.
- Decreased appetite.
- Diarrhoea.
- Nausea.
- Vomiting.
- Generally minimal.
- Injection site reaction (erythema, swelling, pruritus).
- Abdominal distension.
- Decreased appetite.
- Diarrhoea.
- Nausea.
- Vomiting.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
For enhanced fat breakdown and targeted fat burning.
Adds direct lipolysis and targeted fat burning to the appetite- and expenditure-driven deficit.
Suggested for synergistic effects on liver fat, metabolism, and growth hormone support — liver fat being something Mazdutide already reduces.
Synergistic on hepatic fat, metabolism, and GH support. The hepatic overlap is the interesting part: Mazdutide's glucagon arm already improves hepatic fat metabolism, and tesamorelin's visceral-fat action operates on the same compartment.
- Lipo-C
For energy, detoxification, and liver support during rapid weight loss.
Energy, detoxification, and hepatic support through a period of rapid loss.
Rotate between cycles rather than combine, to prolong the metabolic effects.
Cycle-level rotation rather than co-administration, to prolong metabolic effect. Consistent with the severe-grade caution on the GLP2-T entry against combining GLP peptides on receptor redundancy grounds.
Listed alongside GLP2-T as a compound to rotate with between cycles.
Same rotation logic — alternate at cycle level to preserve receptor sensitivity.
- B12
For improved mood, energy, and appetite regulation.
Mood, energy, and appetite regulation support during the deficit.
Dosing figures have been reviewed and units are recomputed from the stated protocol.